WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation ...
The positive results from the double-blind period of the RISE UP Phase 2 study, which were presented at the 65 th American Society of Hematology (ASH) Annual Meeting & Exposition in December 2023, ...